Abstract 43P
Background
Camrelizumab is a humanized PD-1 monoclonal antibody. We sought to analyse the antitumour activity and toxicity of camrelizumab in advanced lung cancer to explore benefit subgroups and optimal treatments. Preliminary data had been previously presented.
Methods
This is a multicentre, prospective cohort study of advanced lung cancer in Jiangsu province, China. Patients with advanced lung cancer received at least one course of camrelizumab-based treatment regimens. Tumor responses were assessed by RECIST 1.1 after every 2 or 3 months by CT or MRI. Primary endpoint is progression-free survival (PFS).
Results
Between August 7, 2019 to February 2, 2021, we screened 480 pts with advanced lung cancer, of whom 468 eligible pts were enrolled and received study treatment. 400 pts (85.5%) had at least one post-treatment tumor assessment. As of data cutoff (June 30, 2021), the median follow-up was 8.2 months. In the ITT population (n=468), 138 (29.5%), 229(48.9%), and 33(7.1%) pts showed partial response (PR), stable disease (SD), and progression disease (PD), respectively. The ORR, DCR was 29.5%, 78.4%. The median PFS was 8.8 months (95% CI, 7.6-10.3), the median OS was 22.0 months ( 95% CL 19.0-not reached). The ≥3 grade AEs included anemia (5.8%, 27/468), neutropenia (3.0%, 14/468), leucopenia (3.0%, 14/468), thrombocytopenia (1.7%, 8/468), reactive cutaneous capillary hyperplasia (RCCEP) (1.5%, 7/468), checkpoint inhibitor pneumonitis (0.85%, 4/468). No treatment-related deaths occurred.
Table: 43P
Baseline characteristics of all enrolled patients
| Characteristic | Patients (N=468) |
| Median age | 65.00 (57.00-71.00) |
| Gender, no. (%) | |
| Male | 357 (76.28%) |
| Female | 111 (23.72%) |
| Age, no. (%) | |
| <70yr | 324 (69.23%) |
| ≥70yr | 144 (30.77%) |
| Pathological type, no. (%) | |
| Adenocarcinoma | 259 (55.34%) |
| Squamous | 140 (29.91%) |
| SCLC | 45 (9.62%) |
| Others | 24 (5.13%) |
| Previous treatment lines, no. (%) | |
| No previous treatment | 139 (29.7%) |
| First-line | 197 (42.09%) |
| ≥Second-line | 132 (28.21%) |
| Combination therapy with camrelizumab, no. (%) | |
| Monotherapy | 50 (10.68%) |
| Combined chemotherapy | 316 (67.52%) |
| Combined with antiangiogenesis | 100 (21.36%) |
| Others | 2 (0.43%) |
Conclusions
This Real-world study showed current clinical practice of advanced lung cancer in China, and camrelizumab showed consistent efficacy in the treatment of advanced lung cancer as previous trials. [ChiCTR1900026089].
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.